The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

摘要: We analyzed the association between achievement of early complete cytogenetic response (CCyR) and event-free survival (EFS) overall (OS) in patients with newly diagnosed chronic myeloid leukemia phase treated imatinib 400 mg (n = 73), or 800 daily 208), second- generation tyrosine kinase inhibitors 154). The CCyR rates were 87%, 91%, 96%, respectively (P .06); major molecular (MMR) 77%, 89%, .05). Their 3-year EFS 85%, 92%, 97% .01), OS 93%, 97%, 100% .18), respectively. By landmark analysis, 3-, 6-, 12-month had significantly better outcome: 98%, 98% 99%, respectively, compared 83%, 72%, 67% 95%, 90%, 94%, who did not achieve a CCyR. Among achieving at 12 months, depth was associated differences EFS. In conclusion, second induced higher MMR than imatinib. remains determinant outcome regardless whether is achieved not.